This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases [02.22.2019] – [Microbial communication] sallieq | home:diseases [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 9: | Line 9: | ||
Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below. | Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below. | ||
- | [[home: | + | [[home: |
===== What is a chronic inflammatory disease? ===== | ===== What is a chronic inflammatory disease? ===== | ||
Line 40: | Line 40: | ||
===== Microbial communication ===== | ===== Microbial communication ===== | ||
- | Here we show that an EHEC luxS mutant, unable to produce the bacterial autoinducer, | + | Here we show that an EHEC luxS mutant, unable to produce the bacterial autoinducer, |
- | The contribution of cell-cell signaling and motility to bacterial biofilm formation. | + | The contribution of cell-cell signaling and motility to bacterial biofilm formation. |
| | ||
- | Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.(({{pubmed> | + | Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.(({{pmid> |
| | ||
Line 63: | Line 63: | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 118: | Line 119: | ||
- | < | + | < |
| | ||
more options | more options | ||
Line 151: | Line 152: | ||
PMS: | PMS: | ||
- | http:// | + | https:// |
- | < | + | < |
</ | </ | ||
Line 179: | Line 180: | ||
< | < | ||
Date: 2011-05-10 13:23:42 | Date: 2011-05-10 13:23:42 | ||
- | Reply: | + | Reply: |
Korean J Urol. 2011 vol. 52(3) pp. 194-9 | Korean J Urol. 2011 vol. 52(3) pp. 194-9 | ||
Line 201: | Line 202: | ||
From: ChrisMavo | From: ChrisMavo | ||
Date: 2011-05-10 13:29:58 | Date: 2011-05-10 13:29:58 | ||
- | Reply: | + | Reply: |
Can someone explain what they mean by nanobacteria? | Can someone explain what they mean by nanobacteria? | ||
Line 212: | Line 213: | ||
From: Bane | From: Bane | ||
Date: 2011-05-10 14:14:45 | Date: 2011-05-10 14:14:45 | ||
- | Reply: | + | Reply: |
ChrisMavo wrote: Can someone explain what they mean by nanobacteria? | ChrisMavo wrote: Can someone explain what they mean by nanobacteria? | ||
Line 220: | Line 221: | ||
- | http:// | + | https:// |
</ | </ | ||
Line 228: | Line 229: | ||
High levels of Epstein–Barr virus in COPD | High levels of Epstein–Barr virus in COPD | ||
- | http:// | + | https:// |
Line 249: | Line 250: | ||
- | http:// | + | https:// |
Line 275: | Line 276: | ||
From: LeeDate: 2011-11-01 07:44:01 | From: LeeDate: 2011-11-01 07:44:01 | ||
- | Reply: | + | Reply: |
Line 288: | Line 289: | ||
From: eClaire | From: eClaire | ||
Date: 2011-11-01 11:07:07 | Date: 2011-11-01 11:07:07 | ||
- | Reply: | + | Reply: |
Line 307: | Line 308: | ||
PMID: 21376827 | PMID: 21376827 | ||
- | </ | + | </ |